Atlas Trials

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Clinical trial NCT06123754 · RECRUITING

Trial details

NCT number
NCT06123754
Sponsor
3D Medicines (Sichuan) Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2023-11-17
Primary completion
2027-12-30
Enrollment
390

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.